Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma

To evaluate the long-term local control, survival rate, acute and late radiation related toxicities, quality of life after reducing high risk primary tumor clinical target volumes (CTVp1) in non-metastatic nasopharyngeal carcinoma treated with IMRT.

Trial Details

NCT ID
NCT05994170
Phase
NA
Sponsor
Zhongshan People's Hospital, Guangdong, China
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Reduction CTVp1
  • Non-reduction CTVp1
Locations (sample)
  • Zhongshan, Guangdong, China|22.52306,113.37912

Key Eligibility Criteria

  • histologic confirmation of nonkeratinizing nasopharyngeal carcinoma(WHO II-III);
  • newly diagnosed stage I to IVa according to the American Joint Committee on Cancer-Union for International Cancer Control 8th edition stage-classif…
  • nasopharyngeal mass confined to one side of nasopharynx and did not exceed the midline(the line between the nasal septum and the midpoint of spinal…
  • planned to receive curative IMRT, Chemotherapy drugs should be administered according to Chinese Society of Clinical Oncology (CSCO) guidelines dep…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →